Advertisement
Blogs
Subscribe to Pharmaceutical Processing Blogs

The Lead

When Will We Learn?

July 23, 2014 | by Mike Auerbach, Editor In Chief | Comments

Humans are a strange lot. We are more than willing to believe just about any product claim in the hopes that an easy solution to our problem can be found inside a pill, tablet or liquid.           

TOPICS:

OpenFDA – the Good, the Bad, and the Ugly

July 21, 2014 3:39 pm | by Brian Overstreet, CEO, AdverseEvents | Comments

In an ideal world, OpenFDA could usher in a world of new and improved tools and products that would improve patient safety and adherence, increase physician awareness of drug safety dangers, assist healthcare decision makers who are driving prescribing behavior with better decision support, and lower the overall cost of care by reducing avoidable side effects. But we don’t live in an ideal world.

TOPICS:

Like Peanut Butter and Chocolate

July 16, 2014 3:02 pm | by Mike Auerbach, Editor In Chief | Comments

Some things just seem to naturally go together – peanut butter and chocolate is one of those combinations – especially in the form of peanut butter cups. Bacon and eggs is another, as is peanut butter and jelly, pizza and beer and numerous other tasty combinations.

TOPICS:

As Pfizer Fights it Out in Britain, US Lawmakers are Making Their Move in the Long Game

May 16, 2014 9:03 am | by Brian Williamson, Managing Director, Jumpstart | Comments

While British attention in the Pfizer-AstraZeneca takeover battle has been focused on clashes between MPs and Pfizer chief executive Ian Read, events have been unfolding across the Atlantic which could have an infinitely greater bearing on where the pharma giant eventually conducts its business.

TOPICS:
Advertisement

How Consumer IT Trends are Affecting Manufacturing Software

May 15, 2014 9:02 am | by Greg Goodwin, Research Associate, LNS Research | Comments

It’s 2014, and that means there are a handful of ways you could be perusing this and any other sentences on your reading queue, daily to-do list, etc. While it’s certainly possible you printed it out, it’s far more likely that you’re viewing it on your desktop or laptop or, increasingly from smaller mobile devices like tablets or even your smartphone, perhaps with your window for your favorite game app temporarily minimized.

TOPICS:

Let’s Not Get Too Excited Over Pancreatic Cancer Drug Trial Results

May 7, 2014 3:50 pm | by Mike Auerbach, Editor in Chief | Comments

Last week there was much excitement and press coverage regarding the results of a Phase III drug study for pancreatic cancer. The company that developed the drug issued a press release, the Pancreatic Cancer Action Network issued a press release – both extolling the new drug’s ability to increase the life expectancy of those with pancreatic cancer.

TOPICS:

Small Workstations, Large Benefits

April 30, 2014 3:06 pm | by Julie Ackerman, Senior Director PR and Communications, PMMI, The Association for Packaging and Processing Technologies | Comments

Regardless of which stage a product is entering the pharmaceutical production line, keeping the work flow moving seamlessly without sacrificing safety and quality is paramount to any operation. Enter the compact workstation.     

TOPICS:

Smart Packaging

April 16, 2014 10:36 am | by Mike Auerbach, Editor-in Chief | Comments

While smart companies consider the final packaging of their product concurrently with the development of the product, sometimes it’s evident that even the smartest companies fail to consider every aspect of their packaging when it finally comes in contact with the consumer.

TOPICS:

Ranbaxy: Lessons and Opportunities

April 10, 2014 8:48 am | by Girish Malhotra, President, EPCOT International | Comments

Will Sun’s latest acquisition change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?                    

TOPICS:
Advertisement

How Will Big Data Affect Manufacturing? Manufacturers Weigh In

April 2, 2014 4:00 pm | by Greg Goodwin, Research Associate, LNS Research | Comments

The current buzz-term “Big Data” may be slightly misleading in the strictest sense. The concept is nothing new. Most manufacturers are quite accustomed to having “big,” some might say huge, amounts of data flowing throughout their organizations, but have historically lacked the context that gives that data actionable meaning—giving birth to the oft used phrase, “data rich, but information poor.”

TOPICS:

Dust Off That Tinfoil Hat: Vaccinations

March 21, 2014 5:23 pm | by Nikita Ernst, Associate Editor | Comments

The controversy over vaccinations is back in the spotlight, after a Colorado bill passed tightening the loophole that allows parents to choose not to vaccinate, and actress Kristen Cavalarri spoke out against vaccinations claiming a connection with autism. What's more frightening is the frequency of outbreaks of diseases we thought we'd eradicated. 

TOPICS:

Sorry Dr. Spengler - Print is Not Dead

March 4, 2014 3:36 pm | by Mike Auerbach, Editor in Chief | Comments

Harold Ramis, one of the great comedic geniuses of my generation and arguably one of the greatest of all time – passed away recently. For those that know of him, and for those that don’t his resume of comedy classics include Animal House, Ghostbusters, Groundhogs Day, and Caddyshack among a slew of other movies.

TOPICS:

What Flu Data Tells Us

February 27, 2014 8:55 am | by Mike Auerbach, Editor in Chief | Comments

In the past I have railed against misinformation on the web and those who use this misinformation to support their beliefs. In particular I have spoken at length about the misinformation concerning vaccinations – that there has been no credible evidence – ever – that vaccination cause any type of permanent maladies or side effects. And yet – people still think vaccines are evil and should be avoided.

TOPICS:

The ‘Brand’ Value of Integrity and Product Traceability in the Pharmaceutical Supply Chain

February 20, 2014 8:34 am | by Tom Singer, Principal at Tompkins International | Comments

Serialization and traceability can be powerful tools to combat drug counterfeiting and the pharmaceutical grey market. This is hardly a new concept, and many voices have been raised in their favor. But not all players in the pharmaceutical industry have rushed to implement them.

I’ve Seen the Future of Drug Delivery and It’s a Bear

February 11, 2014 3:15 pm | by Mike Auerbach, Editor in Chief | Comments

When I was a kid – a long, long time ago – you either took your medicine or died. At least that’s what my mother told me. Medicine back then never tasted good – it wasn’t supposed to – it was supposed to make you feel better – end of discussion.

What Do The Recent Ranbaxy Citations Teach Us?

February 6, 2014 8:12 am | by Girish Malhotra, President & Founder, Epcot International | Comments

The recent Ranbaxy citation (UCM382514) is worth the review as it gives us cause and effect relationship between the state of pharmaceutical manufacturing and regulations.            

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading